A carregar...
MDSC as a Mechanism of Tumor Escape from Sunitinib Mediated Anti-Angiogenic Therapy
Sunitinib is a receptor tyrosine kinase inhibitor (TKI) that is front-line therapy for metastatic renal cell carcinoma (mRCC). Its antitumor activity is related to its ability to block tumor cell and tumor vasculature cell signaling via several TKI receptors (i.e. vascular endothelial growth factor...
Na minha lista:
| Main Authors: | , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2011
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3109226/ https://ncbi.nlm.nih.gov/pubmed/21315783 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.intimp.2011.01.030 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|